Okay. Thank you, Richard. And moving over to the pipeline review. This slide covers CAM2029 across three programs: acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease. The two near-term events are the FDA decision in acromegaly in the US and the SORENTO readouts, of course, in GEP-NET. CAM2029 is approved in the EU, the UK, Australia, and now also Canada under the trade name Oczyesa in Europe and Australia, and Oczyesa XR in Canada. In the US, the FDA accepted our NDA resubmission for Oczyesa in July with a PDUFA date of December 18th. The review is progressing. The complete response letter in June related solely to a GMP inspection at a third-party manufacturing site, and that reinspection has not yet taken place. We are in dialogue with the agency regarding its timing, and we cannot at this moment predict it. That is why we have prepared a contingency plan, and it is now being prepared for submission.
We have manufactured CAM2029 at our secondary site in the US, completed stability work, and completed a phase one bioequivalence study in 130 healthy volunteers, which demonstrated bioequivalence between products from the two sites. Additionally, it was completed successfully, I should say. Additionally, the US site recently completed an FDA GMP inspection. The FDA has been informed of the site change. And the information is now with the review team. Adding the site to the application would be considered a major amendment, and under FDA practice, a major amendment can extend the review goal date by three months. We will take that decision in dialogue with the agency and in good time, before the current PDUFA date on the 18th of December, and we will provide information on any updates to the timelines as received.
So there is an alternative path to approval. Either way, the aim is the same: a robust, flexible supply chain in good time ahead of the GEP-NET submission, which is the largest opportunity for us in the near and mid-term future.
That brings me to two. SORENTO, the largest randomized study of a somatostatin receptor ligand in GEP-NET, enrolled 332 patients in 12 countries, with progression-free survival as the primary endpoint. We expect to reach the target of 194 events around year-end, with topline results in the first quarter of 2027. Those are the expectations. Some 38,000 patients with metastatic GEP-NET are treated with these drugs in the US alone, so a positive outcome opens a substantially larger market opportunity than acromegaly. In polycystic liver disease, new data from the Positano extension studies are due by the end of the year, and we will decide on the next steps together with the SORENTO study and SORENTO results. The next milestones, then, are the FDA decision in acromegaly with 18th December as the current target date and SORENTO top-line data expected in the first quarter of next year. In the early pipeline, CAM2056, our once-monthly semaglutide, has moved into phase two. B, the trial and ethics approvals came in the third quarter and since quarter end. We have dosed the first participants in parallel. Development of a final product design, including the autoinjector pen, is progressing to plan. Our partnership is also on track with Eli Lilly. We are developing long-acting incretins since the option exercise for Amylin agonists in June. We have three programs now running in parallel with Gubra. We are developing a long-acting PTH analog and continuing preparations towards the first clinical trial with the selected lead candidate. So here is the design of the phase two study for CAM2056. We have just started in obesity and overweight. The rationale for this study comes from our Phase 1b study, where monthly CAM2056 showed potential for faster and greater reductions in body weight and glucose than weekly semaglutide with a similar safety and tolerability profile. The Phase 2b study tests higher doses over longer periods of time. 150 participants are randomized 1:1:1 to CAM2056 at 20mg or 10mg, each reached after dose escalation periods, or to placebo. The primary endpoint is relative weight change at week 36. Results are expected in the first half of 2028. We expect the study to show potential for further weight loss with the convenience of once-monthly dosing. So, before going into priorities, I would like to give a note on our commercial leadership. Richard Jameson, here in the room, our Chief Commercial Officer, has decided to retire at the year-end. Richard joined us in 2016 as our first commercial hire and built our commercial organization in Europe, Australia, and the Middle East. Thank you Richard. From everybody at Camurus. We have thoroughly enjoyed our time together, and fortunately, Richard will continue with us as an advisor. From January 1st, Samantha Nickerson takes over as SVP, International Commercial, and member of the Executive Management Team with responsibilities for Europe, Australia, and the rest of the world. Richard Jameson continues to lead our North American business, and Sam has led the UK, which has become one of our largest markets. I look forward to working with her in her new role. Now, over to priorities and a summary. Q3 was a record quarter for Camurus, with strong growth and a 44% margin without one-offs. We reiterate our outlook with results now expected in the upper half of the ranges. This gives us a strong base. Profitable since 2022 and now with 4.4 billion SEK in cash.
From here, there are a number of priorities. Commercial execution is one. Strengthening our leadership in opioid dependence and continuing the launch in acromegaly and preparing for the GEP-NET pipeline. With the anticipated FDA approval decision for Oczyesa and the SORENTO readout early next year. And finally, our partnerships and business development, where we continue to evaluate new opportunities that complement our portfolio. We entered this period from a position of strength with a clear path to continued value creation for patients and shareholders. And with that, thank you so much for your attention.
And let's open up for questions. And we are now ready for questions.